2024
PO0116 Design and Characterization of a Brachytherapy Applicator with Modulated Shielding (MOSH) for the Treatment of Cervical Cancer
Schwipper C, Mullane S, Draeger E, Chen Z, Rivard M, Tien C. PO0116 Design and Characterization of a Brachytherapy Applicator with Modulated Shielding (MOSH) for the Treatment of Cervical Cancer. Brachytherapy 2024, 23: s92. DOI: 10.1016/j.brachy.2024.08.134.Peer-Reviewed Original ResearchDose distributionBrachytherapy applicationsOAR dosesIr-192TG-43 dose calculation formalismShield geometryReduces dose to OARAAPM TG-43 formalismShielding materialsDose calculation formalismHigh-Z shieldingReduced OAR dosesCalculated dose distributionsTG-43 formalismDose-volume objectivesDose to OARsTreatment of cervical cancerHDR brachytherapy applicatorsHigh-risk clinical target volumeIr-192 sourceImproved dose distributionClinical target volumeSparing OARsTOPAS MCYb-169
2022
Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
Damast S, Tien CJ, Young M, Altwerger G, Ratner E. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic. Journal Of Contemporary Brachytherapy 2022, 14: 66-71. PMID: 35233237, PMCID: PMC8867238, DOI: 10.5114/jcb.2022.113058.Peer-Reviewed Original ResearchOverall treatment timeHR-CTV DCervical cancerMucosal toxicityMedian high-risk clinical target volumeHigh-risk clinical target volumeCOVID-19 pandemicLocal control outcomesPre-COVID cohortClinical target volumeMagnetic resonance imagingGastrointestinal eventsRetrospective reviewCC patientsEarly outcomesCOVID groupMedian numberInpatient resourcesInterstitial brachytherapyGrade 2Local controlResonance imagingSeparate weeksTarget volumePatients